CA-THE-MOPRIA-ALLIANCE
10.9.2020 10:02:10 CEST | Business Wire | Press release
The Mopria® Alliance , a global non-profit organization providing universal standards and solutions for print and scan, today announced Android 11 includes new print capabilities and enhancements contributed by the Alliance in collaboration with the Google Android team.
A new “Share-to-Print” feature of the Android Default Print Service enables users to print images and documents from thousands of social media and productivity applications directly from their Android device. Practically any Android app that allows users to share files such as JPEG, BMP, PNG, GIF and PDF, now also includes a convenient and simple option to print those items as well.
Additionally, the “Share-to-Print” path for photo printing supports specific enhancements to ensure best fit and higher resolution on the printed page. These enhancements result in high-quality prints, regardless of aspect ratio of the photo or size of the print.
“With this update, we set out to integrate print features that would make the lives of mobile users easier and continue to push the envelope of what we can provide in the Default Print Service,” said Ingrid Kelly, Chairperson of the Board at the Mopria Alliance. “We achieved those goals in the Android 11 update, and we are excited to continue to invest in and demonstrate our commitment to providing an enhanced printing experience for Android users.”
For people wanting to maximize the features available in their printers that may not be supported by the Default Print Service, the update adds on-the-fly selection of other brand-specific print services and the Mopria Print Service . Users are able to select and install these additional print services directly in their print workflow to enable even more print features.
To date, Mopria print technology has been installed on more than 2 billion devices, including Windows PCs and laptops, Android phones and tablets, FireOS tablets and ChromeOS notebooks. Mopria print technology is designed to simplify desktop printing and mobile printing to more than 4,000 printer models and more than 120 million Mopria certified printers .
The Mopria Alliance membership represents many of today’s global printer businesses, OS providers, device manufacturers and software vendors. In addition to the founding companies, Canon, HP, Samsung and Xerox, Mopria Alliance members include Adobe, Brother, EFI, Epson, Fuji Xerox, Huawei, Konica Minolta, Kyocera, Lexmark, Microsoft, OKI Data, Pantum, Primax, Qualcomm, Ricoh, Toshiba, Xiaomi and YSoft.
The new Default Print Service features will be available to Android users who update to Android version 11. For the latest list of Mopria certified printers and print accessories, please visit https://mopria.org/certified-products .
About the Mopria® Alliance
The Mopria® Alliance is a non-profit membership organization of leading global technology companies with the mission of providing universal standards and solutions for print and scan. With a focus on mobility and modern productivity trends, Mopria technology is used to allow users to interact intuitively and seamlessly with a printer, multi-function printer or scanner, regardless of brand. Learn more at www.mopria.org . Print. Scan. Go.
Android is a trademark of Google Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom